Tanja Crnjevic-Badovinac
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Journal: The Lancet. Oncology
Published: January 19, 2023
Correction to: Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
Journal: Cancer chemotherapy and pharmacology
Published: September 24, 2021
Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics.
Journal: Journal of clinical pharmacology
Published: December 15, 2020
Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
Journal: Cancer chemotherapy and pharmacology
Published: December 01, 2020
Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
Journal: Journal of clinical pharmacology
Published: October 02, 2018
Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.
Journal: Journal of the National Cancer Institute
Published: August 04, 2017
Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 25, 2017
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Journal: The Lancet. Oncology
Published: January 12, 2017
Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.
Journal: Breast cancer research and treatment
Published: February 27, 2016
Last Updated: 09/26/2026